SEC Filing: Form 4
Statement of changes in beneficial ownership of securities
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will also be available for 1-on-1 meetings with investors. Presentation Details Company Presentation: Monday, September 11, 2023 at 7:00 AM ET Speaker: David Domzalski, President and Chief Executive Officer Registration: Webcast Link The replay of the webcast will…
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication selection in Q4 2023 and initiating a Phase 1 trial in Q1 2024 BRIDGEWATER, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30,…
Current report